The Role of Non-pharmacological Treatments of Irritable Bowel Syndrome: A Literature Review
DOI:
https://doi.org/10.12775/JEHS.2025.81.59983Keywords
Irritable bowel syndrome, Low FODMAP Diet, Treatment, Hypnotherapy, Mindfulness, Psychological TreatmentAbstract
Introduction and purpose: Irritable bowel syndrome (IBS) is among the most frequently diagnosed gastrointestinal disorders posing a substantial burden on healthcare systems and presenting ongoing clinical challenges. IBS significantly affects quality of life because it is usually associated with chronic abdominal pain and altered bowel habits. Therapeutic approaches encompass both pharmacological and non-pharmacological strategies. Given the incomplete understanding of its pathophysiology, first-line treatment should prioritize non-pharmacological interventions, which are devoid of adverse effects. This article aims to give you an overview of the trials that have looked at the effects of non-pharmacological management of irritable bowel syndrome and to discuss their role in the treatment of IBS.
Brief description of the state of knowledge: The group of most important non-pharmacological interventions in IBS treatment includes dietary modifications, particularly the low-FODMAP diet, as well as psychological therapies, including cognitive behavioral therapy, gut-directed hypnosis, and mindfulness-based interventions. Data from meta-analyses and randomized controlled trials (RCTs) highlight their efficacy in symptom reduction and quality of life improvement. A key consideration is the potential synergy between dietary and psychological approaches, as supported by emerging evidence.
Conclusion: Low-FODMAP diet and psychological interventions, including cognitive behavioral therapy, gut-directed hypnosis, and mindfulness, are effective treatment strategies for irritable bowel syndrome. The analyzed studies, including meta-analyses and randomized controlled trials, confirm their significant impact on symptom reduction and improvement in patients’ quality of life. Given the incomplete understanding of IBS pathophysiology, non-pharmacological approaches should be considered first-line treatments, as they minimize the risk of adverse effects.
References
[1] Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders [published correction appears in Gastroenterology. 2006 Aug;131(2):688]. Gastroenterology. 2006;130(5):1480-1491. doi:10.1053/j.gastro.2005.11.061
[2] Eriksson EM, Andrén KI, Kurlberg GK, Eriksson HT. Aspects of the non-pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11439-11449. doi:10.3748/wjg.v21.i40.11439
[3] Rome IV Criteria—Rome Foundation. Available online: https://theromefoundation.org/rome-iv/rome-iv-criteria/!!!
[4] Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Dec;5(12):e8. doi: 10.1016/S2468-1253(20)30349-6.]. Lancet Gastroenterol Hepatol. 2020;5(10):908-917. doi:10.1016/S2468-1253(20)30217-X
[5] Galica AN, Galica R, Dumitrașcu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life. 2022;15(2):174-179. doi:10.25122/jml-2022-0028
[6] Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8867-8885. doi:10.3748/wjg.v20.i27.8867
[7] Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021;131(7-8):709-715. doi:10.20452/pamw.16067
[8] Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management [published correction appears in Gut. 2008 Dec;57(12):1743]. Gut. 2007;56(12):1770-1798. doi:10.1136/gut.2007.119446
[9] Dimidi E, Whelan K. Food supplements and diet as treatment options in irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(8):e13951. doi:10.1111/nmo.13951
[10] Patel R, Wong D. Current state of the non-pharmacological management of irritable bowel syndrome: an up-to-date review of the literature. Intern Med J. 2025;55(2):186-199. doi:10.1111/imj.16586
[11] Krasaelap A, Sood MR, Li BUK, et al. Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2020;18(9):1987-1994.e2. doi:10.1016/j.cgh.2019.10.012
[12] Irritable bowel syndrome in adults: diagnosis and management. London, United Kingdom: National Institute for Health and Care Excellence; 2017.
[13] Goyal O, Batta S, Nohria S, et al. Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome: A prospective, randomized trial. J Gastroenterol Hepatol. 2021;36(8):2107-2115. doi:10.1111/jgh.15410
[14] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. doi:10.1136/gutjnl-2021-324598
[15] Wang XJ, Thakur E, Shapiro J. Non-pharmaceutical treatments for irritable bowel syndrome. BMJ. 2024;387:e075777. Published 2024 Dec 16. doi:10.1136/bmj-2023-075777
[16] Bertin L, Zanconato M, Crepaldi M, et al. The Role of the FODMAP Diet in IBS. Nutrients. 2024;16(3):370. Published 2024 Jan 26. doi:10.3390/nu16030370
[17] Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71(6):1117-1126. doi:10.1136/gutjnl-2021-325214
[18] Black CJ, Ford AC. An evidence-based update on the diagnosis and management of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. Published online January 21, 2025. doi:10.1080/17474124.2025.2455586
[19] Van den Houte K, Colomier E, Routhiaux K, et al. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. Gastroenterology. 2024;167(2):333-342. doi:10.1053/j.gastro.2024.02.008
[20] Nybacka S, Törnblom H, Josefsson A, et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial [published correction appears in Lancet Gastroenterol Hepatol. 2024 Jun;9(6):e9. doi: 10.1016/S2468-1253(24)00122-5.]. Lancet Gastroenterol Hepatol. 2024;9(6):507-520. doi:10.1016/S2468-1253(24)00045-1
[21]Williamson A. What is hypnosis and how might it work?. Palliat Care. 2019;12:1178224219826581. Published 2019 Jan 31. doi:10.1177/1178224219826581
[22] Peters SL, Gibson PR, Halmos EP. Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: A retrospective evaluation. Neurogastroenterol Motil. 2023;35(4):e14533. doi:10.1111/nmo.14533
[23] Flik CE, Laan W, Zuithoff NPA, et al. Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(1):20-31. doi:10.1016/S2468-1253(18)30310-8
[24] Lövdahl J, Törnblom H, Ringström G, Palsson OS, Simrén M. Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55(12):1501-1511. doi:10.1111/apt.16934
[25] Häuser W. Gut-directed hypnosis and hypnotherapy for irritable bowel syndrome: a mini-review. Front Psychol. 2024;15:1389911. Published 2024 Jun 3. doi:10.3389/fpsyg.2024.1389911
[26] Brenner DM, Ladewski AM, Kinsinger SW. Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2024;22(2):222-234. doi:10.1016/j.cgh.2023.09.013
[27] Kinsinger SW. Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag. 2017;10:231-237. Published 2017 Jul 19. doi:10.2147/PRBM.S120817
[28] Everitt HA, Landau S, O'Reilly G, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019;68(9):1613-1623. doi:10.1136/gutjnl-2018-317805
[29] Kenwright M, McDonald J, Talbot J, Janjua K. Do Symptoms of Irritable Bowel Syndrome Improve when Patients Receive Cognitive Behavioural Therapy for Co-morbid Anxiety Disorders in a Primary Care Psychological Therapy (IAPT) Service?. Behav Cogn Psychother. 2017;45(5):433-447. doi:10.1017/S1352465817000200
[30] Owusu JT, Sibelli A, Moss-Morris R, van Tilburg MAL, Levy RL, Oser M. A pilot feasibility study of an unguided, internet-delivered cognitive behavioral therapy program for irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(11):e14108. doi:10.1111/nmo.14108
[31] Mohebbi Z, Firoozabadi A, Naini MA, Sharif F, Keshtkaran Z, Heydari N. Effect of Hypnotism on the Severity of Gastrointestinal Symptoms and Quality of Life in Individuals With Irritable Bowel Syndrome. J Psychosoc Nurs Ment Health Serv. 2022;60(5):55-62. doi:10.3928/02793695-20211014-04
[32] Ghandi F, Sadeghi A, Bakhtyari M, Imani S, Abdi S, Banihashem SS. Comparing the Efficacy of Mindfulness-Based Stress Reduction Therapy with Emotion Regulation Treatment on Quality of Life and Symptoms of Irritable Bowel Syndrome. Iran J Psychiatry. 2018;13(3):175-183.
[33] Zomorrodi S, Rasoulzadeh Tabatabaie SK, Azadfallah P, Ebrahimidaryani N, Arbabi M. Long Term Effects of Mindfulness on Quality of life in Irritable Bowel Syndrome. Iran J Psychiatry. 2015;10(2):100-105.
[34] Naliboff BD, Smith SR, Serpa JG, et al. Mindfulness-based stress reduction improves irritable bowel syndrome (IBS) symptoms via specific aspects of mindfulness. Neurogastroenterol Motil. 2020;32(9):e13828. doi:10.1111/nmo.13828
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Oliwia Wiktoria Mentel, Mikołaj Łabuda, Adrianna Bogucka , Teresa Sowińska , Agnieszka Szema, Jakub Sikora , Aleksandra Słojewska , Karolina Knychalska , Agata Kotkowiak , Klaudia Królikowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 252
Number of citations: 0
